Jaguar Health’s Napo submits funding application to BARDA for NP-300

Napo Pharmaceuticals has submitted a Stage 1 funding application to the Biomedical Advanced Research and Development Authority for development of NP-300, the company’s novel drug product candidate for the symptomatic relief and treatment of moderate-to-severe diarrhea, with or without concomitant antimicrobial therapy, from bacterial, viral and parasitic infections including Vibrio cholerae, the bacterium that causes cholera. BARDA, part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, supports advanced research and development of medical countermeasures and is a component of the Public Health Emergency Medical Countermeasures Enterprise. As announced, Napo’s Investigational New Drug application for NP-300 was activated by the U.S. Food and Drug Administration in September 2022. In support of the IND application filing, the company received partial financial support for certain IND-enabling preclinical toxicity studies from the National Institute of Allergy and Infectious Diseases. NIAID is part of the National Institutes of Health.